留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

人类乙醛脱氢酶II及其激动剂的研究进展

田巍 王涛 郑灿辉 董国强 吕加国 朱驹

田巍, 王涛, 郑灿辉, 董国强, 吕加国, 朱驹. 人类乙醛脱氢酶II及其激动剂的研究进展[J]. 药学实践与服务, 2013, 31(2): 94-97,112. doi: 10.3969/j.issn.1006-0111.2013.02.004
引用本文: 田巍, 王涛, 郑灿辉, 董国强, 吕加国, 朱驹. 人类乙醛脱氢酶II及其激动剂的研究进展[J]. 药学实践与服务, 2013, 31(2): 94-97,112. doi: 10.3969/j.issn.1006-0111.2013.02.004
TIAN Wei, WANG Tao, ZHENG Can-hui, DONG Guo-qiang, LV jia-guo, ZHU Ju. Progress on Human aldehyde dehydrogenase II and its agonists[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(2): 94-97,112. doi: 10.3969/j.issn.1006-0111.2013.02.004
Citation: TIAN Wei, WANG Tao, ZHENG Can-hui, DONG Guo-qiang, LV jia-guo, ZHU Ju. Progress on Human aldehyde dehydrogenase II and its agonists[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(2): 94-97,112. doi: 10.3969/j.issn.1006-0111.2013.02.004

人类乙醛脱氢酶II及其激动剂的研究进展

doi: 10.3969/j.issn.1006-0111.2013.02.004

Progress on Human aldehyde dehydrogenase II and its agonists

  • 摘要: 人类乙醛脱氢酶II (aldehyde dehydrogenasesII,ALDH2) 具有脱氢酶和酯酶等多种酶的功能,ALDH2活性的增强将减轻因酒精、缺血等多种因素引起的肝脏、心肌损伤及某些癌症的发生。本文通过对国内外文献的分析、整理和归纳,较为全面的介绍了ALDH2及其激动剂的研究现状。
  • [1] 毛根年,李 鑫,瞿建波.乙醛脱氢酶及其医疗领域研究进展[J].天然产物研究与开发,2011,23:193.
    [2] Wojciech J, Emilia K, Magdalena LD, et al. Alcohol Dehydrogenase (ADH) and Aldehyde Dehydrogenase (ALDH) as Candidates for Tumor markers in Patients with Pancreatic Cancer[J]. J Gastrointestin Liver Dis,2011, 20:255.
    [3] Jose C,Jimenez L, Emma WG, et al.The maize ALDH protein superfamily:linking structural features to functional specificities[J]. BMC Structural Biology,2010, 10:43.
    [4] 何 岚,彭 军.线粒体醛脱氢酶对心脏保护作用的研究进展[J].中国药理学通报,2009,25:1548.
    [5] 罗怀荣,张亚平.乙醛脱氢酶2(ALDH2)基因研究进展及其与饮酒行为的关系[J].遗传,2004,26:263.
    [6] Che HC, Li HS, Daria MR. Mitochondrial aldehyde dehydrogenase and cardiac diseases[J]. Cardiovascular Research,2010,88:51.
    [7] Samantha PM, Hina YRV, Che HC, et al. Alda-1 is an agonist and chemical chaperone for the common human aldehyde dehydrogenase 2 variant[J]. Nature Structural & Molecular Biology,2010,17:159.
    [8] Chen CB.Crystal structure of aldehyde dehydrogenase and methods 0f use tilereof[J].World intellectual property organization,2009,18:1.
    [9] Curtis GS, Pei X, Henry W,et al.Structure of mitochondrial aldehyde dehydrogenase:the genetic component of ethanol aversion[J]. Structure,1997,5:701.
    [10] Jiali W, Haigang W, Panpan H, et al. Inhibition of Aldehyde Dehydrogenase 2 by Oxidative Stress Is Associated with Cardiac Dysfunction in Diabetic Rats[J]. MOL MED, 2011,17:172.
    [11] Grant RB, Marie HD, Daria MR,et al. Aldehyde Dehydrogenase 2 in Cardiac Protection:A New Therapeutic Target[J]. TCM, 2009,19:159.
    [12] 刘非凡,唐 瑛,陈忠庆,等.地塞米松治疗双硫仑样反应的临床和实验研究[J]. 内科急危重症杂志,2008,14:205.
    [13] 陈玉国,张 运.乙醛脱氢酶2与硝酸酯耐药关系的研究进展[J].心血管病学进展,2010,31:50.
    [14] Martin WH, Sonja S, Michael W, et al. Inhibition of aldehyde dehydrogenase type 2 attenuates vasodilatory action of nitroglycerin in human veins[J]. The FASEB Journal, 2008,22:2561.
    [15] 王群英,刘新伟.硝酸甘油及线粒体乙醛脱氢酶对心肌保护作用的研究进展[J].心血管病学进展,2010,31:708.
    [16] Grant RB, Marie HD, Che HC, et al. Activation of aldehyde dehydrogenase 2 (ALDH2) confers cardioprotection in protein kinase C epsilon knockout mice[J]. Journal of Molecular and Cellular Cardiology,2010,48:757.
    [17] Eric NC, Marie HD, Daria MR. Time-dependent and ethanol-induced cardiac protection from ischemia mediated by mitochondrial translocation of εPKC and activation of aldehyde dehydrogenase 2 [J]. J Mol Cell Cardiol, 2009, 46:278.
    [18] Che H C, Lihan S, Daria MR. Mitochondrial aldehyde dehydrogenase and cardiac diseases[J]. Cardiovascular Research,2010, 88:51.
    [19] Perez M, Samantha YH, Vanam R, et al. Alda-1 is an agonist and chemical chaperone for the common human aldehyde dehydrogenase 2 variant[J]. Nature Structural & Molecular Biology,2010, 17:159.
    [20] Matteo B, Antonius CF, Gorren M, et al. Characterization of the East Asian Variant of Aldehyde Dehydrogenase-2[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2010,285:943.
    [21] Grant RB, Marie HD, Daria MR. Aldehyde Dehydrogenase 2 in Cardiac Protection:A New Therapeutic Target[J]. TCM, 2009,19:159.
    [22] Samantha PM, Hina Y, Ram V, et al. Alda-1 is an agonist and chemical chaperone for the common human aldehyde dehydrogenase 2 variant[J]. Nature Structural & Molecular Biology, 2010,17:159.
    [23] Feldman RI, Weiner H. Horse liver aldehyde dehydrogenaseII Kinetics and mechanistic implications of the dehydrogenase and esterase activity[J]. J Biol Chem, 1972,5:267.
    [24] Takahashi K,Weiner W. Nicotinamide adenine dinucleotide activation of the esterase reaction of horse liver aldehyde dehydrogenase dehydrogenase[J].Biochemistry,1981,20:2720.
    [25] Mukerjee N,Pietruszko R. Human mitochondrial aldehyde dehydrogenase substrate specificity:comparison of esterase with dehydrogenase reaction[J]. Arch Biochem Biophys, 1992, 299:23.
    [26] Perez MS, Hurley TD. Coenzyme isomerization is integral to catalysis in human aldehyde dehydrogenase[J]. Biochemistry, 2003,42:7100.
    [27] Hammen PK, Allali HA, Hallenga K, et al. Multiple conformations of NAD and NADH when bound to human cytosolic and mitochondrial aldehyde dehydrogenase[J]. Biochemistry,2002,41:7156.
    [28] Suzuki Y, Ogawa S,Sakakibara Y. Chaperone therapy for neuronopathic lysosomal diseases:competitive inhibitors as chemical chaperones for enchancement of mutant enzyme activities[J]. Perspect Medicin Chem, 2009,3:7.
    [29] Lowe ED, Gao GY, Johnson LN,et al. Structure of daidzin, a naturally occurring anti-alcohol-addiction agent in complex with human mitochondrial aldehyde dehydrogenase[J]. J Med Chem,2008,51:4482.
    [30] Eun JC, Hak CK, Young CS, et al. Four Flavonoids from Echinosophora koreensis and their Effects on Alcohol Metabolizing Enzymes[J]. Arch Pharm Res, 2009, 32:851.
    [31] 汤子春,邹 坤,陆海华.开口箭与筒鞘蛇菰提取物醒酒作用机制的研究[J].时珍国医国药,2007,18:2958.
  • [1] 俞苏纯, 毛亚佩, 戴菲菲.  达雷妥尤单抗致3级输注相关反应1例 . 药学实践与服务, 2024, 42(2): 86-88. doi: 10.12206/j.issn.2097-2024.202304004
    [2] 孙湘沛, 高兴, 赵凤平, 王文涛, 张天亦, 田巍, 郑灿辉, 陈新.  醛脱氢酶2与人类疾病的关系及其小分子激动剂研究 . 药学实践与服务, 2024, 42(1): 6-11. doi: 10.12206/j.issn.2097-2024.202302038
    [3] 赖彦岚, 黄爱文, 陈官旭, 陈婷婷, 赵丽君, 廖小兰, 郭秀强, 吴刚, 宋洪涛.  SGLT-2抑制剂及GLP-1受体激动剂治疗2型糖尿病的心血管获益:一项系统回顾和网状Meta分析 . 药学实践与服务, 2022, 40(4): 354-358. doi: 10.12206/j.issn.1006-0111.202109108
    [4] 赖彦岚, 黄爱文, 张丽丽, 廖小兰, 赵丽君, 宋洪涛.  SGLT-2抑制剂和GLP-1受体激动剂的心血管安全性研究进展 . 药学实践与服务, 2020, 38(6): 496-500, 567. doi: 10.12206/j.issn.1006-0111.202006061
    [5] 陶春, 杨慧丹, 黄爱文, 陈珍珍, 张倩, 宋洪涛.  复方阿达帕林软膏的制备与稳定性研究 . 药学实践与服务, 2019, 37(1): 46-50,68. doi: 10.3969/j.issn.1006-0111.2019.01.011
    [6] 万素馨, 向毅, 罗亚玲.  多奈哌齐联合美金刚治疗阿尔茨海默病的有效性及安全性系统评价 . 药学实践与服务, 2018, 36(3): 260-264,281. doi: 10.3969/j.issn.1006-0111.2018.03.015
    [7] 朱韵.  东菱克栓酶联合银杏达莫注射液治疗突发性耳聋疗效观察 . 药学实践与服务, 2012, 30(1): 60-60,66. doi: 10.3969/j.issn.1006-0111.2012.01.017
    [8] 鲍华燕, 严君, 李珂, 刘鹏.  脂氧素A4、保护素D1、ResolvinD1抑制多种激动剂引起的NFκB的活化 . 药学实践与服务, 2012, 30(3): 185-188. doi: 10.3969/j.issn.1006-0111.2012.03.008
    [9] 赵婷, 沈甫明.  NALP3炎性复合体在阿尔茨海默病中的作用 . 药学实践与服务, 2011, 29(2): 81-82,88.
    [10] 李蔚.  醋酸曲普瑞林(达菲林)致过敏1例 . 药学实践与服务, 2009, 27(3): 164-164.
    [11] 时兢, 赵敏, 谢卫星, 喻立新, 袁惠英.  乌拉地尔治疗急性左心衰竭与其它血管扩张剂疗效比较 . 药学实践与服务, 2007, (5): 297-299.
    [12] 陈素来, 孙志军.  阿司米唑致皮肤瘙痒、皮疹1例 . 药学实践与服务, 2004, (3): 134-134.
    [13] 郑礼宝, 黄卫东, 陈静, 张弘, 付江洲.  阿达帕林凝胶治疗寻常痤疮临床观察 . 药学实践与服务, 2002, (1): 10-11,28.
    [14] 尹玉琴, 邹静, 代祖荫.  口服阿司咪唑致下肢水肿1例 . 药学实践与服务, 1996, (6): 364-364.
    [15] 张勇彪, 刘卫, 殷明.  治疗阿尔茨海默病药物的研究近况 . 药学实践与服务, 1996, (3): 134-137.
    [16] 缪朝玉, 苏定冯.  阿洛地平——一种新的长效钙拮抗剂 . 药学实践与服务, 1992, (4): 1-4.
    [17] 王建国.  阿米替林急性中毒1例报告 . 药学实践与服务, 1991, (4): 59-60.
    [18] 许榕椿, 苏开仲, 许世民.  新型钙拮抗剂苄普地尔评介 . 药学实践与服务, 1989, (3): 27-28.
    [19] 吡丁醇—支气管扩张药(选择性β2—肾上腺素受体激动剂) . 药学实践与服务, 1988, (4): 34-34.
    [20] 申庆亮, 李健.  催眠剂氟硝安定引起健忘1例 . 药学实践与服务, 1987, (4): 35-35.
  • 加载中
计量
  • 文章访问数:  3344
  • HTML全文浏览量:  453
  • PDF下载量:  331
  • 被引次数: 0
出版历程
  • 收稿日期:  2012-04-26
  • 修回日期:  2012-11-12

人类乙醛脱氢酶II及其激动剂的研究进展

doi: 10.3969/j.issn.1006-0111.2013.02.004

摘要: 人类乙醛脱氢酶II (aldehyde dehydrogenasesII,ALDH2) 具有脱氢酶和酯酶等多种酶的功能,ALDH2活性的增强将减轻因酒精、缺血等多种因素引起的肝脏、心肌损伤及某些癌症的发生。本文通过对国内外文献的分析、整理和归纳,较为全面的介绍了ALDH2及其激动剂的研究现状。

English Abstract

田巍, 王涛, 郑灿辉, 董国强, 吕加国, 朱驹. 人类乙醛脱氢酶II及其激动剂的研究进展[J]. 药学实践与服务, 2013, 31(2): 94-97,112. doi: 10.3969/j.issn.1006-0111.2013.02.004
引用本文: 田巍, 王涛, 郑灿辉, 董国强, 吕加国, 朱驹. 人类乙醛脱氢酶II及其激动剂的研究进展[J]. 药学实践与服务, 2013, 31(2): 94-97,112. doi: 10.3969/j.issn.1006-0111.2013.02.004
TIAN Wei, WANG Tao, ZHENG Can-hui, DONG Guo-qiang, LV jia-guo, ZHU Ju. Progress on Human aldehyde dehydrogenase II and its agonists[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(2): 94-97,112. doi: 10.3969/j.issn.1006-0111.2013.02.004
Citation: TIAN Wei, WANG Tao, ZHENG Can-hui, DONG Guo-qiang, LV jia-guo, ZHU Ju. Progress on Human aldehyde dehydrogenase II and its agonists[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(2): 94-97,112. doi: 10.3969/j.issn.1006-0111.2013.02.004
参考文献 (31)

目录

    /

    返回文章
    返回